Long-acting β2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) are burdened by the potential risk of inducing cardiovascular serious adverse events (SAEs) in COPD patients. Since the risk of combining a LABA with a LAMA could be greater, we have carried out a quantitative synthesis to investigate the cardiovascular safety profile of LABA/LAMA fixed-dose combinations (FDCs).
Rogliani, P., Matera, M.g., Ora, J., Cazzola, M., Calzetta, L. (2017). The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: A quantitative synthesis. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 12, 3469-3485 [10.2147/COPD.S146338].
The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: A quantitative synthesis
Rogliani P.
;Cazzola M.;Calzetta L.
2017-01-01
Abstract
Long-acting β2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) are burdened by the potential risk of inducing cardiovascular serious adverse events (SAEs) in COPD patients. Since the risk of combining a LABA with a LAMA could be greater, we have carried out a quantitative synthesis to investigate the cardiovascular safety profile of LABA/LAMA fixed-dose combinations (FDCs).I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
